Login to Your Account



NewCo News

Ixchelsis Gets $14M for Premature Ejaculation Drug

By Cormac Sheridan
Staff Writer

Wednesday, August 7, 2013
Ixchelsis Ltd., a start-up with roots in Pfizer Inc.'s UK R&D facility at Sandwich, in Kent, has raised more than $14 million from TVM Life Science Ventures VII fund for development of an oxytocin antagonist, IX-01, for treating premature ejaculation.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription